• Malaria Vaccines Revolutionize Global Health: RTS,S and R21 Offer Promising Solutions

  • Mar 26 2025
  • Length: 3 mins
  • Podcast

Malaria Vaccines Revolutionize Global Health: RTS,S and R21 Offer Promising Solutions

Listen for free

View show details

  • Summary

  • In recent developments, malaria continues to be a significant public health concern, particularly in regions with high transmission rates. Over the past two days, several key updates have emerged regarding both the disease itself and the progress of malaria vaccines.

    In the Democratic Republic of Congo (DRC), a deadly outbreak has been confirmed to be caused by malaria. According to the National Public Health Institute, tests have verified that the disease is responsible for the deaths of 52 people and has affected nearly 200 others. This outbreak highlights the ongoing need for effective malaria control measures in such regions[1].

    On a more positive note, significant strides have been made in the development and implementation of malaria vaccines. The World Health Organization (WHO) has recommended two malaria vaccines, RTS,S/AS01 (RTS,S) and R21/Matrix-M, for widespread use in children living in areas with moderate to high malaria transmission. These vaccines have shown substantial efficacy in reducing malaria cases and related mortality.

    The RTS,S vaccine, developed by GlaxoSmithKline Biologicals, was the first to receive a WHO recommendation for widespread use in October 2021. It has been shown to reduce clinical malaria by 39%, severe malaria by 30%, and all-cause mortality by 13% in children. The R21 vaccine, approved by the WHO in 2023, has similar efficacy and is particularly effective in highly seasonal malaria settings[2][4].

    Both vaccines have been integrated into routine childhood vaccinations in several countries. As of December 2024, 17 countries in Africa have introduced these vaccines as part of their national malaria control strategies. Additional countries are expected to follow suit in 2025, with at least 30 African countries planning to include the malaria vaccine in their childhood immunization programs[4].

    The rollout of these vaccines is expected to have a high public health impact, with modelling estimates suggesting that they could prevent up to half a million child deaths over 12 years if scaled up to all GAVI-eligible countries. The vaccines are also highly cost-effective, with GAVI supporting their introduction through an exceptional time-limited co-financing policy that makes the vaccines affordable, with many countries paying as little as $0.20 per dose[4].

    The availability of two safe and effective malaria vaccines has alleviated concerns about vaccine supply, ensuring that there will be sufficient doses to meet the high demand. This dual-vaccine approach is expected to significantly reduce malaria cases and deaths, especially in regions where the disease is most prevalent[4].

    In summary, while malaria remains a critical health issue, as evidenced by the recent outbreak in the DRC, the advancement and widespread implementation of malaria vaccines offer a promising solution. The ongoing rollout of RTS,S and R21 vaccines is poised to save tens of thousands of young lives annually, marking a significant step forward in the global fight against malaria.
    Show More Show Less
Show More Show Less

What listeners say about Malaria Vaccines Revolutionize Global Health: RTS,S and R21 Offer Promising Solutions

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available